fb_script

First class of future research leaders feel fibre might find a faster cure

A world first program designed to help medical researchers in type one diabetes develop their leadership skills to help take innovations out of the lab and into the real world has graduated its first intake. The graduates, announced in Canberra on June 26th 2018, have already put their skills into practice, securing funding to look at a dietary supplement that could stop type one diabetes. Read More

Insulin pump with predictive low glucose management function reduces hypoglycaemia exposure in young people with type 1 diabetes

A T1DCRN funded clinical trial published in Diabetes Care has shown that a pump with the ability to suspend insulin delivery when blood glucose levels begin to fall can reduce hypoglycaemic episodes without deterioration in glycaemic control.

Members of the PLGM study team L-R: Dr Mary Abraham, Prof Tim Jones, Dr Charles Czank, Prof Liz Davis and Ms Jennifer Nicholas

The integration of real-time continuous glucose monitoring systems and pump therapy has been an important milestone in the management of type 1 diabetes, and advances in the technology field offers the potential to further improve clinical outcomes.

Read More

Results from the Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AdDIT)

The international AdDIT trial group have this month published results of a four year clinical trial in The New England Journal of Medicine, finding that ACE inhibitors and statins did not change the primary outcome – the albumin to creatinine ratio – compared to placebo in adolescents with type 1 diabetes (T1D).  Read More

Immunotherapy found to be safe in pilot study of people with T1D

A pilot clinical trial in the US has found a new immunotherapy treatment to be safe in people with new onset type 1 diabetes (T1D).

After clinical presentation of T1D, beta cell loss continues progressively in most people until C-peptide levels, a marker of endogenous insulin production, is absent or present in very low levels. Despite intensive research efforts for more than 20 years, no therapy is currently available to prevent beta cell loss in T1D.

Read More

The need to screen for additional autoimmune diseases

People with type 1 diabetes (T1D) often develop other autoimmune diseases, but the frequency and predictive factors for development have not been characterised.

lab research

While the mechanisms for T1D are still under investigation, it is thought there are common immune system pathways that may be similar across more than one, or all autoimmune diseases.  Read More

Carb counting: Could there be a better way?

The current gold standard for calculating mealtime insulin in people with type 1 diabetes is carbohydrate counting using the carbohydrate to insulin ratio – the amount of insulin that will cover a certain amount of carbohydrates. Recent research and clinical observations from continuous glucose monitoring (CGM) data has seen that people can experience delayed high blood glucose levels (hyperglycaemia) hours after eating a meal high in fat and/or protein.  Read More

Sanofi and Lexicon Pharmaceuticals partner on new non-insulin therapy for type 1 diabetes

JDRF partner Sanofi and Lexicon Pharmaceuticals have announced a new collaboration to develop and commercialise a new oral drug for the treatment of type 1 diabetes.

Nadav Kidron, CEO of Oramed Pharmaceuticals, poses for a photo in Jerusalem

The drug is called sotagliflozin and is used in conjunction with insulin to help improve blood glucose levels by blocking glucose absorption in the kidneys and the gut.  Read More

World first trial to slow type 1 diabetes development in children

The Australian Type 1 Diabetes Clinical Research Network has partnered with the Immune Tolerance Network to launch a new Australian clinical trial to slow the development of newly diagnosed type 1 diabetes in children.

Tocilizumab

The EXTEND-P trial is expected to begin recruitment in March 2016 to test the ability of an existing drug called tocilizumab to preserve beta cell function. Tocilizumab, sold under the brand name Actemra, is currently approved for use in children with juvenile arthritis. Read More

T1DCRN awards $14 million for type 1 diabetes clinical research

The Type 1 Diabetes Clinical Research Network (T1DCRN) announced today that over $14 million in grants have been awarded to Australian researchers for clinical research projects commencing in 2016.

RFA1 Announcement 090915

This funding forms part of the $35 million funding awarded to the T1DCRN by the Australian Research Council, and will support five innovative programs targeting a broad range of T1D research areas including: Read More